Chindex Announces Agreement With Hudson RCI; Focuses on Growth of Critical Care Product Offerings to Hospital Markets.

Business Editors/Health & Medical Writers

BETHESDA, Md.--(BUSINESS WIRE)--March 22, 2000

Chindex International, Inc. (NASDAQ: CHDX) (U.S.-China Industrial Exchange, Inc.), the leading independent American company providing Western healthcare products and services in the People's Republic of China, today announced it has agreed to distribute certain products of Hudson RCI (Hudson) in China.

Under the agreement announced today, Chindex will begin distribution of certain Hudson anesthesia and respiratory care products for the hospital markets in China beginning this spring.

Hudson is a world leader in the development and manufacture of disposable products for the respiratory care and anesthesia markets.

"We are very pleased to add Hudson to our growing product portfolio serving the OR and other critical care environments here in China," Roberta Lipson, Chindex Chairperson, President and CEO commented in Beijing. "Chindex has established itself as a leading supplier of products to critical care markets in China over the past several years. We already have a great deal of experience with this market segment through our years of work with Tyco Healthcare/Kendall. Our agreement to distribute Hudson products not only insures a seamless supply of these products to the market, but also a continuing expansion of our long term growth program."

Mr. Gary Meyers, Director of International Sales and Marketing for Hudson said, "We are pleased that Chindex will be distributing these products in China. China presents a tremendous opportunity for us as a primary supplier of anesthesia and respiratory care products on a worldwide basis. We are confident our new relationship with Chindex will help ensure our ongoing success."

James H. Spear, Jr., Vice President of Products Distribution for Chindex commented on the company's growth program: "Our Chindex Products Distribution business has been supplying high quality consumable products to hospitals throughout China for several years now. We currently utilize a network of approximately 250 sub-dealers. Our products are used in hundreds of hospitals every day. We have focused our expansion in the areas of critical care and interventional cardiology. We expect that the product lines offered by Hudson will be a significant new addition to our overall program."

Chindex is a leading American company in healthcare in the Greater Chinese marketplace including Hong Kong and Macau.

It provides representative and distribution services to a number of major multinational companies including Acuson (diagnostic ultrasound scanners), Johnson & Johnson (clinical chemistry analyzers), Guidant (interventional cardiology products including stents, balloon catheters, and guide wires) and Tyco/Kendall Healthcare Products (including brands such as Davis & Geck, Sherwood, Kendall, Sheridan, and Curity).

It also provides healthcare services through the operations of its private hospital corporation in China. With over eighteen years of experience, approximately 330 employees, and operations in the United States, China and Hong Kong, the Chindex strategy is to expand its cross-cultural reach by providing leading edge technologies, quality products and services to Greater China's professional communities.

Further company information may be found at the Chindex website, www.chindex.com.

The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services and other risks identified in the Company's SEC filings.

Actual results, events and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.

The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.